Image For Activity Cover
ITLPPAAD2402 - CME/CMLE - Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
Course Description

This podcast highlights HRR testing in prostate cancer and the need for testing and optimal testing. The discussion features an expert pathologist and oncologist.

Faculty/Authors

Heather Cheng, M.D., Ph.D.
Professor, Division of Hematology and Oncology, University of Washington
Professor, Clinical Research Division, Fred Hutchinson Cancer Center
Director, Prostate Cancer Genetics Clinic, Fred Hutch
Adjunct Professor, Laboratory Medicine and Pathology, UW
Seattle, Washington
 
Colin C. Pritchard, M.D., Ph.D.
Associate Professor of Laboratory Medicine, University of Washington (UW)
Director of the Genetics and Solid Tumors Laboratory at UW Medical Center
Seattle, Washington

CME/CMLE Credit: 0.75
Estimated Completion Time: 0.75 hour
Format: Online Educational Activity

Method of Participation
To complete the activity and receive credit, the participant must complete the podcast activity. CME certificates will be provided on-line. 

Physician Competencies: Medical Knowledge, Patient Care

Accreditation Statement:
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME).

Credit Designation Statement: The American Society for Clinical Pathology (ASCP) designates this journal-based CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASCP designates this activity for a maximum of .75 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.
 
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time

Commercial Support
This activity is funded by an independent educational grant from Pfizer.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Review the Faculty Disclosures.
  3. Click Go to Course to view an overview of the modules in this course.
  4. Click Access to begin the course.
  5. Review the Educational Activity.
  6. Submit the course Evaluation.
  7. Enter the maximum number of credits offered and click Claim CME to register credit.

Faculty Disclosure

Technical Considerations

Release Date: 3/15/2024
Review Date:
Expiration Date: 3/15/2026

Course Objectives
Following completion of this activity, you will be able to:
  • Describe the utility of targeting PARP in prostate cancer with alpha reductase inhibitor combinations. 

  • Understand key findings from recent phase III randomized clinical trials. 

  • Describe standards for testing in prostate cancer, particularly concerning sample sources and the choice between next-generation sequencing (NGS) and polymerase chain reaction (PCR) methods. 

  • Understand the usefulness of coordination between healthcare providers when utilizing HRR testing in prostate cancer management. 

Summary
Availability: On-Demand
Credit Offered:
0.75 CME/CMLE Credit
Powered By